As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...

The semaglutide shortage has officially ended ... The initiative helped pressure the Chinese government to clean up the air in Beijing and was later expanded to dozens of cities around the world.

Until two years ago, such discussion was of little practical relevance since there were few treatments for obesity between ...

Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide ...

The drug company DK:NOVO.B NVO UK:0TDD also sells a semaglutide drug under the name Wegovy for weight loss. Back To Top ...

Meanwhile, 10 stocks—predominantly Chinese firms—defied a broader ... has declared that supply of the only real, FDA-approved semaglutide medicines is resolved,” said Dave Moore, NVO ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Semaglutide, and other GLP-1 drugs have been ... It also signed a pact with Chinese biotech firm Innovent late last year, to bring its immunotherapy drug - the biosimilar Sintilimab, to India ...